Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate’s Comparative Effectiveness Language Emphasizes Clinical Over Cost

This article was originally published in The Gray Sheet

Executive Summary

Comparative effectiveness research funding of $1.1 billion passed the House and got approval from the Senate Appropriations Committee as part of an $800 billion-plus economic stimulus package last week; but device firms and some patient and physician groups are pushing for the Senate language to win out when it comes time to reconcile the bills

You may also be interested in...



Former Medicare Officials Urge Reforms To Coverage Process

Four former CMS officials are calling for dramatic changes to Medicare coverage policy that would allow the agency to consider cost in its coverage decision-making, require prior authorization for technologies to ensure compliance with national coverage policies and devote more government resources to clinical research specific to Medicare needs.

Former Medicare Officials Urge Reforms To Coverage Process

Four former CMS officials are calling for dramatic changes to Medicare coverage policy that would allow the agency to consider cost in its coverage decision-making, require prior authorization for technologies to ensure compliance with national coverage policies and devote more government resources to clinical research specific to Medicare needs.

Industry Seeks Collaborative Role In HHS Comparative-Effectiveness Research

Industry leaders are urging federal agencies to keep private firms and trade associations in the loop as they make policy decisions regarding comparative-effectiveness research

Related Content

Topics

UsernamePublicRestriction

Register

MT027063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel